key: cord-0309246-fbicmhe7
authors: Clark, Alexander P.; Wei, Siyu; Krogh-Madsen, Trine; Christini, David J.
title: A model-guided pipeline for drug cardiotoxicity screening with human stem-cell derived cardiomyocytes
date: 2021-09-11
journal: bioRxiv
DOI: 10.1101/2021.09.10.459625
sha: 57a443c6fea15caed1a3b77ce1a77597b7836e08
doc_id: 309246
cord_uid: fbicmhe7

New therapeutic compounds go through a preclinical drug cardiotoxicity screening process that is overly conservative and provides limited mechanistic insight, leading to the misclassification of potentially beneficial drugs as proarrhythmic. There is a need to develop a screening paradigm that maintains this high sensitivity, while ensuring non-cardiotoxic compounds pass this phase of the drug approval process. In this study, we develop an in vitro-in silico pipeline using human induced stem-cell derived cardiomyocytes (iPSC-CMs) to address this problem. The pipeline includes a model-guided optimization that produces a voltage-clamp (VC) protocol to determine drug block of seven cardiac ion channels. Such VC data, along with action potential (AP) recordings, were acquired from iPSC-CMs before and after treatment with a control solution or a low-, intermediate-, or high-risk drug. We identified significant AP prolongation (a proarrhythmia indicator) in two high-risk drugs and, from the VC data, determined strong ion channel blocks that led to the AP changes. The VC data also uncovered an undocumented funny current (If) block by quinine, which we confirmed with experiments using a HEK-293 expression line. We present a new approach to cardiotoxicity screening that simultaneously evaluates proarrhythmia risk (e.g. AP prolongation) and mechanism (e.g. channel block) from iPSC-CMs.

paradigm that maintains this high sensitivity, while ensuring non-cardiotoxic compounds pass 23 this phase of the drug approval process. In this study, we develop an in vitro-in silico pipeline 24 using human induced stem-cell derived cardiomyocytes (iPSC-CMs) to address this problem. 25

The pipeline includes a model-guided optimization that produces a voltage-clamp (VC) protocol 26 to determine drug block of seven cardiac ion channels. Such VC data, along with action 27 potential (AP) recordings, were acquired from iPSC-CMs before and after treatment with a 28 control solution or a low-, intermediate-, or high-risk drug. We identified significant AP 29 prolongation (a proarrhythmia indicator) in two high-risk drugs and, from the VC data, 30 determined strong ion channel blocks that led to the AP changes. The VC data also uncovered 31 an undocumented funny current (If) block by quinine, which we confirmed with experiments 32 using a HEK-293 expression line. We present a new approach to cardiotoxicity screening that 33 simultaneously evaluates proarrhythmia risk (e.g. AP prolongation) and mechanism (e.g. 34 channel block) from iPSC-CMs. 35

In the 1990s, cardiotoxicity was the number one cause for the US Food and Drug 37

Administration to withdraw or restrict the use of a drug on the market (Lasser et al., 2002) . 38

Such drugs were identified because they increased the prevalence of lethal heart arrhythmias 39 (Lasser et al., 2002; Roden, 2005) . It was found that many of these drugs block the human 40 ether-à-go-go related gene (hERG) channel, which is responsible for conducting repolarizing 41 potassium current (IKr) and is known to be protective against the development of arrhythmias. counteract the proarrhythmic effects on hERG by blocking ion channels that conduct current in 49 the opposing direction (e.g. depolarizing calcium and sodium channels), emphasizing the need 50 for multi-channel screening. 51

To address the specificity shortcomings of hERG-based approaches, the Comprehensive 52 in Vitro Proarrhythmia Assay (CiPA) initiative was started in 2013 to guide the development of 53 more accurate preclinical tests (Sager et al., 2014) . The group established a three-step drug 54 screening pipeline that includes: 1) quantifying drug effects on multiple ionic currents using 55 expression line cells, 2) integrating these effects into in silico models and using them to 56 7 122 Figure 1 : An in silico-in-vitro pipeline to determine drug cardiotoxicity risk and mechanism.

Step 1, The Kernik-

Clancy model with experimental artifacts is used to develop a voltage clamp protocol that is specifically designed 124 to isolate currents.

Step 2, Spontaneous, IK1 dynamic clamp and paced AP, and optimized voltage-clamp data is 125 acquired from a patient-derived iPSC-CM before and after drug application.

Step 3, The change in IK1 dynamic 126 clamp and paced AP data from pre-to post-drug application is used to identify AP prolongation, a surrogate 127 8 marker of cardiotoxicity.

Step 4, Changes in voltage-clamp data is used to determine the ion channels targeted by 128 the drug.

Step 5, After identifying the ion channel targeted by the drug, a dose-response curve is developed for 129 each of these ion channels using expression line cells.

We used a model-guided experimental design approach to optimize a VC protocol that 133 isolates the contribution of individual currents at different timepoints. Our rationale for 134 isolating current contributions, similar to our previous work (Groenendaal et al., 2015) , is that 135 this enables tracking changes in individual currents during iPSC-CM drug studies and using these 136 changes to identify ion channel targets. 137

We used the recent Kernik-Clancy iPSC-CM model (Kernik et al., 2019) in the optimization 138 algorithm to simulate a cell's response to VC protocols. Because we expected the protocol to 139 isolate currents during segments that are most sensitive (e.g., <10ms after a voltage step) to 140 experimental artifacts (see Materials and Methods), we added equations that incorporate these 141 effects (e.g. voltage offset, leak current, and series resistance), as was recently shown to be 142 critical (Lei et al., 2020) . 143

We used the genetic algorithm to optimize VC protocols that maximize the current 144 contribution for one of seven ionic currents: IKr, ICaL, INa, Ito, IK1, IKs, and If (Figure 2A , Appendix -145

The durations of the seven protocols ranged from ~1400 ms for Ito to ~3800 ms for 146

IKs. The VC protocols for each current were systematically shortened (see Materials and 147

Methods) and then combined into a single protocol with the segments that maximized the 148 isolation of each ionic current ( Figure 2B ). The resulting optimized protocol was just over 9 9 seconds, i.e., short enough to be run multiple times in each cell both under control conditions 150 and with drug application. 151 152 

We validated the VC protocol by applying it to a different iPSC-CM model (Paci et al., 159 2018 ) and comparing the windows of maximum current. This step provided us with confidence 160 that the VC protocol could isolate currents during the same time windows from a cell with 161 different conductances and kinetics (Appendix - Figure 9 ). 162

We conducted in vitro experiments using isolated iPSC-CMs. The dynamically clamped 165 and paced APs were acquired by injecting a synthetic IK1 model current (Ishihara et al., 2009) 166 into the cells until spontaneous AP generation stopped and the resting membrane potential 167 was below -65 mV. 168

The iPSC-CMs displayed a heterogeneous phenotype ( Figure 3A ), which is consistent 169 with previous work on single-cell iPSC-CMs (Garg et al., 2019) . Figure 3A shows the 170 spontaneous behavior of six cells that were selected to highlight the heterogeneity in the 171 population. By dynamically clamping IK1 and pacing, we were able to elicit APs from all these 172 cells ( Figure 3B ). This finding is consistent with previous work showing the value of IK1 dynamic 

We compared changes in AP features for iPSC-CM data acquired before and after 187 application of cisapride (n=6), verapamil (n=9), quinidine (n=6), quinine (n=9), or DMSO control 188 (n=10). Table I shows AP prolongation after cisapride treatment that is characteristic of such IKr block. 192

Verapamil is a low-risk drug that moderately blocks ICaL and lightly blocks IKr at the 193 concentrations used in this study. Figure 4B shows a verapamil-treated cell that displays AP 194 shortening after verapamil treatment. Most of the shortening in 4B appears to be due to AP 195 triangulation, a morphological change also seen in experimental data from human 196 cardiomyocytes (Britton et al., 2017) . Quinidine and quinine are both high-risk CiPA drugs that 197 block multiple ion channels with a strong affinity for IKr. Both quinidine-(p=.034, Figure 4C ) and 198 quinine-treated (p=.0003, Figure 4D ) cells show AP prolongation after drug application. 199

Verapamil-treated cells showed shortening in the action potential duration at 20% of 200 repolarization (APD20), but the difference between these and control cells was not statistically 201 significant (p=.056, Figure 4E ). Cells that were treated with quinidine and quinine showed a 202 significant prolongation in the action potential duration at 90% of repolarization (APD90) when 203 compared to control cells ( Figure 4F ). These findings agree with the CiPA classification for 204 13 verapamil (low risk), quinidine (high risk), and quinine (high risk). Because APD90 prolongation is 205 an established proarrhythmia risk indicator, these data correctly suggest that quinidine and 206 quinine have proarrhythmic potential at 3x their EFPC. Cisapride-treated cells did not show a 207 significant change in APD90, despite it being a stronger IKr blocker than quinidine and quinine at 208 the concentrations used in this study. This may be because quinidine and quinine also block a 209 small amount of IKs at the concentrations used in this study. Because these drugs block both 

The optimized VC protocol qualitatively identifies drugs that block greater than 30% of an 220 ionic current 221 While the AP data described above was used to identify surrogate markers of drug 222 cardiotoxicity, it did not provide specific information about the drugs' mechanism. To identify 223 the targets of each drug, we compared the average change in VC responses for a given drug to 224 the average change of cells treated with DMSO control. Because the protocol was designed to 225 isolate one specific ionic current during a brief window of the protocol, differences of the 226 changes in each of these seven segments could reveal ionic mechanism. 227

As a demonstration of this approach, Figure 5A shows a representative example of a cell 228 that was treated with quinine. The zoomed-in panel in Figure 5B shows the portion of the VC 229 protocol that maximized the current contribution of IKr relative to the total current. This inset 230 shows a decrease in the total current present after treatment with quinine throughout the time 231 window. The difference is particularly pronounced from 860 ms to 865 ms and from 870 ms 232 to 875 ms, which corresponds to the segments where IKr is predicted by the model to have a 233 large relative contribution compared to the other ionic currents present. According to our 234 modeling work, the 865-870 ms segment is predicted to have the largest amount of IKr, 235 however, in the experiments we found the current to be highly variable in this window because 236 of variations in access resistance among cells. We chose to focus on the 860-865 ms window, 237 because it had the second largest IKr current isolation and was a few milliseconds after a voltage 238 step, generating more consistent results. Figure 5C shows the change in current during the 239 window from 860 ms to 865 ms for all cells in this study, separated by drug. (Table I) , did not show a significant difference in current 256 during this segment. These data suggest that the VC protocol can detect strong IKr block during 257 the model designed IKr segment but fails to detect light block of IKr current. 258 259 

We followed this approach to identify the other major channels that were separately 265 blocked by the protocol. The boxes marked with (*) in Table I indicate currents that were  266 identified as being blocked based on significant changes in current during the corresponding 267 model-identified segment. Importantly, all drugs that blocked more than 30% of a current were 268 correctly identified, and there were no currents that were incorrectly identified as being 269

blocked. This demonstrates that the VC protocol can be used to identify strong blocks of ionic 270 currents with high sensitivity. 271

In addition to focusing on the model-identified segments of the protocol, we also 272 performed a functional t-test where we calculated a p-value for the difference in current 273 18 responses between DMSO-and drug-treated cells at every timepoint during the VC protocol. 274 Figure 5C through 5E shows the segment of the VC protocol where IKr should be isolated. The 275 colored window on the top of each panel shows the timepoints where there is a significant 276 difference (p<.05) between control and drug treatment with cisapride ( Figure 5D ), quinidine 277 ( Figure 5E ), and quinine ( Figure 5F ). The functional t-test identifies a significant difference in the 278 currents between 860ms and 865ms for all three of these IKr blockers. There was no significant 279 difference between DMSO and verapamil during this period. 280

The significance windows identified with a functional t-test were plotted over the entire 281 VC protocol and suggest an agreement with the ionic currents that are blocked by each drug 282 (Appendix - Figures 10-13) . The verapamil-treated cells have a few brief windows of 283 significance and most overlap with segments that the Kernik-Clancy model predicts will have ICaL 284 present. The cisapride-and quinidine-treated cells have longer and more significant windows. 285

Most of the cisapride windows align with segments that the Kernik-Clancy model predicts will 286 have IKr. Most of the quinidine windows align with segments the Kernik-Clancy model predicts 287 will consist of IKr, Ito, ICaL, or IKs. 288

Taken with dynamic clamp AP data, these results indicate that the optimized VC 289 protocol can be used to identify underlying currents responsible for changes in AP morphology. 290

These ion channel targets can be further studied in expression cells to acquire dose-response 291 data for specific drugs. 292

Interestingly, our quinine-treated iPSC-CMs revealed a previously unreported block of If. 294

The protocol identified a significant reduction (p=.0097) in current during the portion of the 295 protocol designed to isolate If. The significance windows that fall after 4000 ms, which includes 296 the portion of the protocol designed to isolated If, align closely with Kernik-Clancy-predicted If 297 ( Figure 6A ). Between 4000 ms and 6000 ms, when the membrane potential is hyperpolarized, 298 there is loss of inward current after quinine treatment. During the second, long holding step 299 between 4500 ms and 5500 ms, the difference between the pre-drug and post-drug traces 300 increases and persists until the voltage is stepped to +50 mV. For the first ~100 ms after this 301 step, the traces flip, with the post-treatment trace showing a reduction in outward current 302 before settling into a similar total current of ~4.5 pA/pF at 6150 ms. These dynamics align 303 closely with If, as it is a positive current at positive holding potentials and will inactivate with a 304 time constant around 40 ms when stepped to +50 mV. Figure 6C In this study, we demonstrated the potential of a novel drug screening pipeline for 344 predictive safety pharmacology. This approach simultaneously identifies surrogate markers of 345 drug proarrhythmia in iPSC-CMs, and information about the drug's underlying cardiotoxicity 346 mechanism. 347

To overcome the difficulty of identifying cardiotoxicity markers and mechanism from 348 individual iPSC-CMs, we developed an optimization algorithm that designed a VC protocol for 349 the purpose of identifying multi-channel drug block. We then acquired optimized VC data, along 350 with dynamic clamp AP data, from iPSC-CMs before and after drug treatment to identify 351 markers of cardiotoxicity (e.g. AP prolongation) and mechanism (e.g. drug targets). This 352 approach is the first of its kind to produce such detailed information about a drug's action from 353 individual iPSC-CM experiments. Using this approach, we also identified a novel block of If by 354 quinine in iPSC-CMs. A similar such block was demonstrated in iPSC-derived neurons (Zou et al., 355 2018), but has never been confirmed in an expression system. We followed up on these 356 findings by conducting a drug-response experiment using a cell line stably expressing HCN1 357 channels, and confirmed that quinine blocks HCN1 at the concentration used in this study. 358

Huxley, 1952), there have been numerous efforts to fit electrophysiological models to less 361 experimental data and to reproduce increasingly complex datasets. Traditional steady-state VC 362 protocols take minutes to acquire and often result in models that poorly reproduce VC data 363 from nonequilibrium states. It has also been desirable to acquire rich VC data for fitting multi-channel models, such 374 as neurons and cardiomyocytes. One such approach focused on quickly sampling the entire 375 dynamic range of a neuronal cell, and using this data to fit model conductance values (Hobbs 376 and Hooper, 2008). More recently, our lab developed a VC protocol that was manually designed 377 to specifically isolate individual currents from a guinea pig cardiomyocyte to improve 378 estimation of channel conductances (Groenendaal et al., 2015) . 379

For both single-and multi-channel applications, most protocols have been designed 380 with the ultimate goal of improving model fits. The current study is a departure from this 381 24 approach in two ways: 1) the model used in this study was included as part of an optimization 382 algorithm that designed the protocol, and 2) the resulting protocol was designed for the 383 specific use of identifying drug targets, not for improving fits. In other words, the optimized 384 protocol has a useful application outside of just improving cell model fits and predictions. 385

The success of this protocol in identifying ion channel targets is dependent on the 386 quality of the underlying cell model (Kernik-Clancy) above, we know that these in silico models can generate interesting hypotheses, simulate in 396 vitro conditions, and guide therapy. However, to the best of our knowledge, this is the first 397 work that shows how in silico models can be used to improve the design, and therefore impact, 398 of cardiotoxicity drug studies. 399

for each channel 401

The GA was designed to isolate individual currents, which resulted in protocols ( Figure  402 2A) that take advantage of the unique gating kinetics for each ion channel. For example, the IKr 403 25 protocol (Appendix - Figure 5) Because this approach only considers spontaneous AP and conduction velocity data, successful 436 estimates of current block is limited to the currents (e.g. IKr, ICaL, and INa) that are sensitive to 437 changes in these data. 438

In the current study, we build upon this work by developing a pipeline that provides 439 both surrogate measures of drug cardiotoxicity and identification of drug block for seven 440 cardiac ion channels. With the HEK-293 study, we showed the potential of using expression cell 441 lines to confirm findings in iPSC-CMs and determine potency at multiple concentrations. 442

This study has some limitations. First, before this approach can be used at scale, it must 444 first be validated with a high-throughput automated patch-clamp system. With this type of 445 system, data acquisition could be 10-100x faster and operators would not need the specialized 446 patch-clamp skill. Because the automated patch-clamp system applies the same protocol 447 identically every time, these studies will likely have more consistent experimental artifact 448 parameters, such as leak and access resistance (Goversen et al., 2018a), and increased power 449 for statistical analyses. Also, the microfluidic administration of drugs in these systems allows for 450 quick wash-on steps, making it possible to acquire data at more concentrations. This would 451 provide dose response data in each cell, which could be used to identify the relative size of the 452 currents present. 453

Second, in addition to improvements made possible by an automated system, some 454 adjustments to the VC protocol and data analysis could improve the mechanistic insights made 455 in future studies. Additional channels besides the seven considered in this study could be 456

included. This is easy to address, by simply adding currents to the VC protocol optimization 457 algorithm. One challenge that would require additional adjustments is to design an algorithm 458 that can tease apart drug effects on ion channel kinetics. An optimization algorithm to address 459 ion channel kinetics would need a target objective that is, likely, very different from the one 460 used in this study. 461

Third, when treated with a high dose of cisapride, the iPSC-CMs in this study did not 462 show significant APD90 prolongation, despite its strong block of IKr. This may be due to the cells 463 having a relatively low density of IKr compared to adult cardiomyocytes. Quinidine and quinine, 464 also strong IKr blockers, did cause significant prolongation. This may have been caused by their 465 small block of IKs, which would further deplete the repolarization reserve of these cells. Further 466 tests with cisapride would be needed to determine whether this was an issue of statistical 467 power. 468

Fourth, the iPSC-CMs often produced an oscillatory current trace when held at large 469 positive voltages (e.g. from 6500 to 9000 ms in the VC protocol). This is likely caused by calcium 470 overload that can occur at high potentials. This could decrease the sensitivity of the protocol to 471 determine strong IKs-blockers. In the future, we would like to test the ability of the protocol to 472 strong blocks of IKs. 473

In this study, we outline a new pipeline for determining drug cardiotoxicity and 475 underlying mechanism by applying a novel VC protocol and IK1 dynamic clamp to iPSC-CMs. By 476 analyzing changes in AP and VC data acquired after drug application, we were able to identify 477 cardiotoxicity markers and currents that were strongly blocked by the drug. We also identified a 478 novel block of If by quinine, which was confirmed using an expression system cell line. In the 479 future, the scalability of this method can be improved with an automated patch clamp system 480 and the detail of the mechanistic insights can be increased by applying this protocol to iPSC-481

CMs at multiple drug concentrations. We think that this cardiotoxicity pipeline could have far-482 reaching effects on how drugs are screened and could ultimately increase the number of safe 483 and effective drugs available to patients. 484

The baseline Kernik-Clancy iPSC-CM model was used in this study (Kernik et al., 2019) . 488

Prior to the VC protocol optimization, the model was run to steady state, and then simulated 489 under voltage clamp at -80 mV for 20 s. We included the simplified experimental artifact 490 29 equations from Lei et al. in our model simulations (Lei et al., 2020) . In this recent study, these 491 artifact equations were incorporated into an ion channel model and shown to produce better 492 fits to experimental data, and with fewer parameters. The effects of these patch clamp artifacts 493 are particularly pronounced within the first few milliseconds after a voltage step (Appendix -494 Figure 1 ). This was an important factor to consider in our optimization because we anticipated 495 the optimal protocols may isolate currents during these windows. This is based on the 496 observation that many existing VC protocols designed to maximize current through a single ion 497 channel (e.g hERG or NaV1.5) often do so within the first few milliseconds after a voltage step, 498

where artifacts most obscure current readings. 499

The following equations summarize the iPSC-CM model and artifact equations used in our 500 simulations: 501 502 

!"# = $% + &%' + () + (* + (+ + ," + -+ &%.

Seal leak current "8, = !"# + 45%6 Observed current 9 = :7; + * "8, Rs compensation 7 = 1 * 7

, 9 + "--− 7 . − 1 7 "8,

The Iion equation is the sum of all ionic currents from the Kernik-Clancy iPSC-CM model. 505

The leak current equation quantifies the amount of contamination caused by an imperfect seal 506 30 between the pipette tip and cell membrane. The observed current is a sum of the leak and ionic 507 currents. The series resistance compensation equation affects the speed with which the cell 508 membrane voltage will reach the command voltage after a step. The membrane voltage 509 differential includes a term for the voltage offset. This term is a catchall offset from the 510 amplifier, electrode, and liquid junction potential. Because we zero the amplifier offset before 511 patching each cell, we assume that this term is equal to our experimental liquid-junction 512 potential (-2.8 mV) in our simulations. The Kernik-Clancy model with experimental artifact was 513 implemented using custom Python code. Below is a list of parameter definitions, along with the 514 values used in our model simulations. 515 516 Each individual in the GA was initialized with a random set of four voltage segments. 527

Each segment could be either a step or ramp between 5 and 1000 ms long and with voltages 528 between -120 and 60 mV. If the segment was a step, the duration was randomly selected 529 between 5 and 1000 ms and the voltage was randomly selected between -120 and 60 mV. If the 530 segment was a ramp, the duration was randomly selected between 5 and 1000 ms, and the 531 start and end voltages were selected between -120 and 60 mV. 532

Evaluation 533

To evaluate the fitness of a VC protocol, we clamped the Kernik-Clancy model, and 534 calculated the percent contribution (C(t)) of the target current at every timepoint during the 535 protocol. 536

In this equation, Ix is the target current and In is any current that contributes to the observed 538 current (Iout). The denominator is the sum of the absolute values for all these currents, including 539 ionic currents and the artifact leak current. The best possible contribution score is one and 540

represents when the target current contributes all the observed current. The worst 541 32 contribution score is zero and represents when the target current is turned off. We calculated 542 the average contribution, C(t), over a 10 ms window at each timepoint and used the highest 543 contribution window value as the fitness score for the protocols. 544

Selection 545

To select the protocols that continue to the next generation, we used k=2 tournament 546 selection with replacement. This means that the GA ran 200 random head-to-head matchups, 547 and the protocol with the higher fitness score in each matchup moved into the mating pool. 548

Because we randomly selected protocols from the same pool for every matchup, it was possible 549

for some individuals to be in multiple matchups, while others were not in any matchups. After 550 all the matchups, there were 200 individuals in the mating pool. It was common for this new 551 pool to include multiple copies of high-fitness protocols. 552

Mating 553

Each individual in the mating pool was paired with one other individual and uniform 554 crossover was applied to create two child individuals. For each pair, there was a 90% chance 555 that the individuals would mate. If the individuals did not mate, the protocols would remain the 556 same and their features would be cloned into two new individuals and placed in the mutation 557 pool. If individuals did mate, there was a 20% chance of swapping each segment in their 558 protocol. The offspring protocols that resulted from the swapping of segments between the 559 two individuals were moved into the mutation pool. 560

Mutation 561

For each protocol in the mutation pool, there was a 90% chance of being selected for 562 mutation. For each segment in a selected protocol, there was a 10% chance of mutation. To 563 mutate the duration of a segment, a random number was selected from a normal distribution 564 centered around zero, with a standard deviation of 47.8 ms, and added to the existing duration. 565

To mutate the voltage of a segment, a random number was selected from a normal distribution 566 centered around zero, with a standard deviation of 6 mV, and added to the existing voltage. If 567 the resulting duration or voltage was outside the bounds (e.g. 5 to 1000 ms or -120 to 60 mV), a 568 new mutation value would be selected until the duration or voltage were valid. Once all 569 protocols were considered for mutation, the population was moved to the next generation 570

where selection begins again. 571

Evaluation, selection, mating, and mutation were repeated for 50 generations. 572

We took the protocol with the highest current contribution for each of the seven ionic 574 currents (Supp Figs II-VIII) and combined them into one large protocol. The durations of the 575 seven protocols ranged from ~1400 ms for Ito to ~3800 ms for IKs (Figure 2A ). Before combining 576 the protocols, we systematically shortened them using a two-step process. First, we removed 577 the portion of the protocol more than 50 ms after the maximum current contribution window. 578

Then, we incrementally removed 10 ms segments from the beginning of the protocol, while 579 ensuring the max current contribution did not decrease by more than 5%. The seven shortened 580 protocols were then connected by 500 ms holding steps at -80 mV. We chose to hold at -80 mV 581 for 500 ms, because all of the protocols were optimized after a -80 mV holding step, and 582 because this is long enough for the kinetics of most ion channels to reach steady state. 583

To validate that the VC protocol isolates current during the same time windows in a cell 584 with different conductance and kinetic parameters, we applied the optimized VC protocol to 585

Sinusoidal voltage protocols for rapid characterisation of ion channel kinetics

High-throughput drug profiling with voltage-and calcium-sensitive fluorescent 760 probes in human iPSC-derived cardiomyocytes

Quantitative 763 comparison of effects of dofetilide, sotalol, quinidine, and verapamil between human ex 764 vivo trabeculae and in silico ventricular models incorporating inter-individual action 765 potential variability

Chemically Defined and Small Molecule-Based Generation of Human Cardiomyocytes HHS 769

Public Access

In vitro 771 safety "clinical trial" of the cardiac liability of drug polytherapy

Cellular Cardiomyoplasty: Methods and Protocols

Machine learning in drug 776 44 development: Characterizing the effect of 30 drugs on the QT interval using Gaussian 777 process regression, sensitivity analysis, and uncertainty quantification

An evaluation of 30 clinical drugs against 780 the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel

Anti-HERG activity 783 and the risk of drug-induced arrhythmias and sudden death

Molecular 787 determinants of pro-arrhythmia proclivity of d-and l-sotalol via a multi-scale modeling 788 pipeline

ICH S7B Note for Guidance on the Nonclinical Evaluation of the Potential for 790

Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals

Int Conf Harmon Tech Requir Regist Pharm Hum Use

Automaticity of iPSC-CMs Depends Strongly on IK1 Model Structure

DEAP: Evolutionary 796 algorithms made easy

Wavelet-based protocols for ion channel electrophysiology

Application of oscillating 847 potentials to the Shaker potassium channel

A computational model of induced pluripotent stem-cell derived cardiomyocytes 850 incorporating experimental variability from multiple data sources

A computational model of induced 853 pluripotent stem-cell derived cardiomyocytes for high throughput risk stratification of 854 KCNQ1 genetic variants

Comparing two mean humidity curves using functional t-tests: Turkey case

OptoDyCE as an automated 858 system for high-throughput all-optical dynamic cardiac electrophysiology

Development 861 of a Human iPSC Cardiomyocyte-Based Scoring System for Cardiac Hazard Identification

Early Drug Safety De-risking

Timing of new 865 black box warnings and withdrawals for prescription medications

Accounting for 868 variability in ion current recordings using a mathematical model of artefacts in voltage-869 clamp experiments

Establishment 872 of an automated patch-clamp platform for electrophysiological and pharmacological 873 evaluation of hiPSC-CMs

Proarrhythmic Risk Using Human Stem-Cell-Derived Cardiomyocytes in a Ca2+ 877

Imaging Assay: Evaluation of 28 CiPA Compounds at Three Test Sites

Human iPSC-based cardiac microphysiological system for drug 881 screening applications

Nonequilibrium response spectroscopy of voltage-sensitive ion 883 channel gating

Automatic 885 optimization of an in silico model of human iPSC derived cardiomyocytes recapitulating 886 49 calcium handling abnormalities

Human in silico drug trials demonstrate higher accuracy than animal 889 models in predicting clinical pro-arrhythmic cardiotoxicity

Optical 894 investigation of action potential and calcium handling maturation of hiPSC-cardiomyocytes 895 on biomimetic substrates

Light-Activated Dynamic Clamp Using 897 iPSC-Derived Cardiomyocytes

Drug-Induced Prolongation of the QT Interval

Rechanneling the cardiac 901 proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research 902

Classifying Drugs by their Arrhythmogenic Risk 904

Using Machine Learning

Beta-Adrenergic Receptor Stimulation Modulates the Cellular 906

Proarrhythmic Effects of Chloroquine and Azithromycin

Development, calibration, and validation of a novel 910 human ventricular myocyte model in health, disease, and drug block

Inversion and 913 computational maturation of drug response using human stem cell derived 914 cardiomyocytes in microphysiological systems

Investigational Treatments for COVID-19 may Increase Ventricular Arrhythmia Risk 918

Cardiac TdP risk stratification modelling of anti-infective compounds including 922 chloroquine and hydroxychloroquine

The Temperature Dependence of Kinetics 924

Associated with Drug Block of hERG Channels Is Compound-Specific and an Important 925 Factor for Proarrhythmic Risk Prediction

A Computational Pipeline to Predict Cardiotoxicity: From 929 the Atom to the Rhythm

Blinded in silico 931 drug trial reveals the minimum set of ion channels for torsades de pointes risk assessment

The Effects of Quinine on 934

Neurophysiological Properties of Dopaminergic Neurons

the Paci iPSC-CM model (Paci et al., 2018) with experimental artifacts. The Paci model, which 586 was originally designed based on different data from the Kernik-Clancy model, can be 587 interpreted as a cell with different kinetic and conductance parameters. This was an important 588 step because of the heterogeneity among iPSC-CMs. 589We found the time windows that maximized the current isolation for each of the seven 590 currents using the the Paci-artifact model and compared those time windows to the Clancy-artifact results (Appendix - Figure 9 ). Five (IK1, Ito, IKr, IKs, and INa) of the seven currents in 592 the Paci model were isolated within 10 ms of the Kernik-Clancy model. The maximum ICaL 593 isolation in the Paci model occurs far from where the current is maximized in the Kernik-Clancy 594 model. However, the Paci model had a current isolation within 5% of its maximum during the 595Kernik-Clancy window. The timepoint for If also differed between the two models. However, 596 these timepoints are near one another and have similar voltage dynamics. These data provide a 597 signal that the Kernik-Clancy-designed protocol is generalizable enough to isolate currents in 598 iPSC-CMs with different kinetics and conductances. 599All code for this pipeline has been made available on the Christini Lab GitHub: 600 https://github.com/Christini-Lab/vc-optimization-cardiotoxicity. commands to the amplifier via the data acquisition card (PCI-6025E;  630 National Instruments, Austin, TX). After immersing the pipette into the extracellular solution, 631 voltage was set to zero, and voltage offset in our recordings was assumed to be equal to the 632 liquid junction potential of -2.8 mV. After contact with a cell was made and a seal of greater 633 than 300 MΩ was established, we waited for the access resistance to decrease below 40 MΩ 634 before starting experiments. The series resistance was 9-40 MΩ for all experiments, and series 635 resistance compensation was set to 70%. The 70% compensation was chosen because larger 636 values caused oscillations during the recordings. 637

Spontaneous, IK1 dynamic clamp, and VC data was acquired before and after drug 639 application. Once access was gained, spontaneous behavior was acquired for >10 s. Dynamic 640 clamp IK1 data was acquired using a custom RTXI module that implemented the Ishihara et al. for all drug solutions. Cells were exposed to the drug solution for >5 minutes, while square 658 pulses were applied to observe changes in the current response. Once the cell had been 659 exposed for >5 minutes, and changes in the current response had stabilized, spontaneous, IK1 660 dynamic clamp, and VC data was acquired by following the same steps above. 661

All results are presented as mean ± standard error of the mean. Significant differences 663 between the DMSO and each drug group were calculated using the SciPy unpaired t-test 664 function in Python, with significance indicating p<0.05. The precise p-value for each statistical 665 test is presented in its corresponding figure. Confidence intervals are set to 95% for each point 666 plot. All statistical analyses were performed using the raw experimental data. For presentation 667 in figures, data were smoothed with a 0.4 ms moving average. 668 A power analysis was not used to make a sample-size estimation because we saw 669 significant differences between groups after experiments conducted on one freshly thawed 670 batch of cells for each drug. 671Analyzing AP features 672 38The resting membrane potential (RMP), action potential amplitude (APA), action 673 potential duration at 20% repolarization (APD20), and action potential duration at 90% 674 repolarization (APD90) were calculated for all dynamically clamped IK1 studies using custom 675 Python code. The RMP was determined by finding the minimum voltage during an AP. The APA 676 was calculated as the difference between the RMP and the maximum voltage during an AP. The 677 APD20 and APD90 were calculated as the duration between the maximum upstroke velocity 678 timepoint and when the cell repolarized to 20% and 90% of its RMP. 679Analyzing VC protocol data 680

A functional t-test (Keser, 2014 ) was used to determine the time windows when current 682 response changes to drug treatment differed from responses to DMSO treatment. We used the 683 following steps to develop a null distribution, conduct a functional t-test, and determine 684 windows of significant difference between DMSO control and drug groups: 685 1. For both the control and drug groups, we calculated the change in current at every 686 timepoint from pre-to post-treatment. 687 2. We developed a null distribution by completing the following step 200 times: we 688 combined and randomly shuffled individuals from the drug and control groups, and then 689 redistributed them into two distinct groups. We calculated a T-statistic (T(t)) at every 690 timepoint. 691 3. We found the t-value at the 95 th quantile of the null distribution and used it as the 692 threshold for determining significant differences between our control and drug groups. 693In other words, the control and drug groups were labeled significantly different at a time 694 39 when the T-value comparing these two groups was greater than the T-value at the 95 th 695 percentile of the null distribution. 696The windows plotted in Figures 5, 6 , and Appendix - Figures 10-13 show where there is a 697 significant difference between the drug and DMSO groups that lasts for more than 1 ms. The 698 functional t-test calculations were completed with custom Python code using the SciPy 699 unpaired t-test function. Cells were stepped to a potential between -20 mV and -120 mV for 3500 ms, decreasing by 10 725 mV steps. Then, cells were stepped to -50 mV for 500 ms to acquire the tail current. Maximum 726 currents were calculated as the average current over the last 800 ms of the hyperpolarizing 727 step. Maximum tail currents were calculated as the average between 8 and 16 ms after the step 728 to -50 mV. 729To measure the dose-response of HCN1 current to quinine treatment, peak currents 730 were measured by stepping from a holding potential of -20 mV to -110 mV for 3500 ms. 731Maximum currents were calculated as the average current over the last 800 ms of the 732 hyperpolarizing step. These traces were acquired three or four times at each dose. The last two 733 traces at each dose, which were acquired >40 s after drug application, were used for analysis. 734Each data point plotted in Figure 7C is an average of the currents from these two traces.